Gene-therapy company Spark Therapeutics shares double in debut

Jan 30 (Reuters) - Shares of Spark Therapeutics Inc more than doubled in their debut, valuing the gene-therapy company at nearly $1.5 billion and underscoring investor's interest in the field that recently produced a million-dollar drug.